Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …

Background Human papillomavirus (HPV) vaccination programmes were first implemented
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …

BACKGROUND: Clinical trials of the 4-valent human papillomavirus (HPV) vaccine
demonstrate high efficacy, but surveillance studies are essential to examine the long-term …

Background Modelling studies have been widely used to inform human papillomavirus
(HPV) vaccination policy decisions; however, many models exist and it is not known whether …

Since 2006, 115 countries and territories have introduced human papillomavirus (HPV)
vaccination programs. Several efforts have been undertaken to evaluate the impact of HPV …

Background Human papillomavirus (HPV) vaccination is safe and effective in preventing
cervical cancer in females. As HPV infections can also induce cancers of the anus, penis …

Background Human papillomavirus (HPV) vaccine was recommended in 2006 for routine
vaccination of US females aged 11–12 years. Most vaccine used through 2014 was …

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

Background Uptake of human papillomavirus (HPV) vaccine remains low in many countries,
although the bivalent and quadrivalent HPV vaccines given as a three‐dose schedule are …

We currently have the knowledge and experience to prevent much of human papillomavirus
(HPV)-related disease burden globally. In many countries where prophylactic HPV …